影响蛋白印迹法检测HIV抗体结果的生物学因素分析

目的探寻导致蛋白印迹法（western blotting,WB）检测结果呈＂HIV抗体不确定＂可能的生物学因素。方法检测经WB确证后结果为＂HIV抗体不确定＂病例乙型肝炎（type B hepatitis,HBV）、丙型肝炎（type Chepatitis,HCV）、梅毒螺旋体（treponemiasis,TP）、HTLV-I/II（human T cell leukemia virus I/II,HTLV-I/II）的感染状况及癌胚抗原（carcino-embryonic antigen,CEA）、抗核抗体（antinuclear antibody,ANA）、甲胎蛋白（α-fetoprotein,AFP）、β2微球蛋白（β2-microglobulin,β2-MG）在血液中的含量,并与文献资料报道的普通人群/健康人比较。结果＂HIV抗体不确定＂病例HCV抗体初筛阳性率、TP抗体阳性率和HTLV-I/II抗体的初筛阳性率均高于普通人群;22.22%的＂HIV抗体不确定＂病例血液中ANA含量高于普通人群,呈阳性或可疑;9.27%的＂HIV抗体不确定＂非孕产妇病例血液中AFP含量高于普通人群。结论＂HIV抗体不确定＂的产生可能与病例感染HCV、TP、HTLV-I/II,病例体内ANA、AFP水平升高有关。

Biological Factors Affecting the Determination of HIV Antibody

Objective To examine the possible biological factors contributing to the observed uncertainty on the measurement of HIV antibody by Western blot. Methods Clinical samples from hepatitis B （HBV）, hepatitis C （HCV）, treponema （TP） and human T cell leukemia virus I/II （HTLV-I/II） infected patients showing uncertain HIV antibody by Western blot were checked for the serum level of carcino-embryonic antigen （CEA）, antinuclear antibody （ANA）, a-fetoprotein（AFP） and β2-microglobulin （β2-MG）. Serum from normal subjects was used as control. Results The rates of sero-positive for HCV, HTLVI/II and TP in these clinical samples were higher than the normal serum. 22.22% of these clinical samples had the level of ANA higher than the normal serum. 9.27% serum samples from non-pregnant women were higher than the normal subjects. Conclusion The observed uncertainty in the determination of HIV antibody is correlated with the patients with HCV, HTLV-I/II and/or TP infection. It is also correlated with the elevated level of serum ANA and/or AFP.